The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme

Today, the Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 20 June – 9 November 2023. Today, the Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C...

Today, the Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 20 June – 9 November 2023.

The company currently holds 12,867,104 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, whereafter the number of own common shares will amount to 14,399,118.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/the-board-of-directors-of-sobi-exercises-authorisation-for-repurchase-of-shares-for-the-purpose-of-securing-the-companys-commitments-under-the-incentive-programme-301855242.html